⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Yposkesi and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Yposkesi
↗Corbeil-Essonnes, France
Yposkesi is a leading European Contract Development and Manufacturing Organization (CDMO) specializing in the manufacturing of viral vectors for gene and cell therapy. Founded in 2016 as a spin-off from the French gene therapy pioneer Genethon, the company provides comprehensive services including process development, analytical development, and GMP manufacturing of lentiviral and adeno-associated virus (AAV) vectors.
In 2021, Yposkesi was acquired by SK Pharmteco, a subsidiary of the South Korean conglomerate SK Holdings, to strengthen SK's global CDMO capabilities in the advanced therapy medicinal products (ATMP) sector. The company operates state-of-the-art facilities at the Genopole innovation campus in Corbeil-Essonnes, France, supporting clients from early clinical development through to commercial-scale production.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2016
Ownership:subsidiary
Status:operating
FUNDING
Investors:SK Pharmteco, Genethon, Bpifrance
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO)
Modalities:Gene therapy, Cell therapy, Viral vectors
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:SK Pharmteco
Acquired By:SK Pharmteco (2021-03-01)
Key Partnerships:Genethon (Founding partner and ongoing collaborator)
COMPETITION
Position:Leader
Competitors:Lonza, Thermo Fisher Scientific (Patheon), Catalent, WuXi AppTec, Fujifilm Diosynth Biotechnologies
LEADERSHIP
Key Executives:
Alain Lamproye - Executive Chairman
Scientific Founders:Genethon
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Yposkesi. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.